Cleo Diagnostics

Cleo Diagnostics EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cleo Diagnostics (COV.AX) as of Nov 3, 2026 is -7.89 M AUD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -3.84 M AUD — a change of 105.46% (lower).

EBITDA

-7.89 MAUD

YoY

105.46%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cleo Diagnostics is 2026 -7.89 M AUD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cleo Diagnostics was 2025 -3.84 M AUD. It decreases by 105.46% lower compared to the previous year.

The Cleo Diagnostics EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
-23,310.00 AUD
Jan 1, 2023
-1.53 M AUD
Jan 1, 2024
-3.55 M AUD
Jan 1, 2025
-3.84 M AUD
Jan 1, 2026
-7.89 M AUD
The Cleo Diagnostics EBITDA history
YEAREBITDAYoY
-7.89 MAUD+105.46%
-3.84 MAUD+8.00%
-3.55 MAUD+131.97%
-1.53 MAUD+6,472.16%
-23,310.00AUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cleo Diagnostics Stock analysis

What does Cleo Diagnostics do? Cleo Diagnostics Ltd develops non-invasive blood-based IVD tests for ovarian cancer detection. The company's three-phased strategy includes the Triage Test for pre-surgical assessment of ovarian masses, the Recurrence Test for post-surgical monitoring of cancer recurrence, and the Screening Test for early detection in asymptomatic women. The CLEO Test Kit detects the protein biomarker CXCL10 in blood samples. These products target healthcare providers, oncologists, and diagnostic laboratories seeking advanced tools for ovarian cancer management. The company generates revenue through the sale of these diagnostic tests and kits to medical institutions and laboratories in Australia and potentially international markets. The Triage Test helps determine malignancy before oncologist referral, the Recurrence Test identifies cancer recurrence after surgery and chemotherapy, and the Screening Test enables early detection in symptom-free women. Cleo Diagnostics Ltd focuses on delivering these specialized tests to address unmet needs in ovarian cancer diagnostics. Revenue streams are derived from the commercialization of these three test phases and the CLEO Test Kit, targeting medical professionals and healthcare facilities requiring accurate and non-invasive diagnostic solutions. Cleo Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Cleo Diagnostics stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cleo Diagnostics is -7.89 M AUD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Cleo Diagnostics changed from -3.84 M AUD to -7.89 M AUD, representing a 105.46% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Cleo Diagnostics since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Cleo Diagnostics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Cleo Diagnostics

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Cleo Diagnostics